Quote | 4D Molecular Therapeutics Inc. (NASDAQ:FDMT)
Last: | $17.40 |
---|---|
Change Percent: | 1.87% |
Open: | $16.83 |
Close: | $17.08 |
High: | $17.6 |
Low: | $16.63 |
Volume: | 982,661 |
Last Trade Date Time: | 07/23/2024 03:00:00 am |
News | 4D Molecular Therapeutics Inc. (NASDAQ:FDMT)
NEW YORK, NY / ACCESSWIRE / July 21, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of 4D Molecular Therapeutics, Inc. ("4D Molecular" or "the Company") (NASDAQ:FDMT). Investors who purchased 4D Molecular securities are encouraged to obtai...
2024-07-20 09:37:01 ET Summary 4D Molecular Therapeutics' share price fell by over 15% in response to its latest data readout related to Wet-AMD therapy 4D-150. Investors reacted negatively to the news, which may be surprising as it seemed to confirm a positive treatment effect an...
Message Board Posts | 4D Molecular Therapeutics Inc. (NASDAQ:FDMT)
Subject | By | Source | When |
---|---|---|---|
znewcar1: $FDMT 38% v2,8M c18.69 f32,4M H19.2999 ml6.58 | znewcar1 | investorshangout | 11/15/2022 10:13:15 PM |
News, Short Squeeze, Breakout and More Instantly...
4D Molecular Therapeutics Inc. Company Name:
FDMT Stock Symbol:
NASDAQ Market:
4D Molecular Therapeutics Inc. Website:
NEW YORK, NY / ACCESSWIRE / July 21, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of 4D Molecular Therapeutics, Inc. ("4D Molecular" or "the Company") (NASDAQ:FDMT). Investors who purchased 4D Molecular securities are encouraged to obtai...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...
Robust reduction in anti-VEGF injection treatment burden through Week 24 achieved in 30 patients at planned Phase 3 dose (3E10 vg/eye) with 89% reduction in annualized injection rate; 93% of patients received 0 or 1 injection and 77% were injection-free Improvement in mean best corr...